AXA launches €440 m private equity healthcare strategy

The Strategy focuses specifically on companies in four core areas: medical devices, biopharmaceuticals, vaccines, and diagnostics.

The strategy seeks investments in companies aiming to deliver healthcare solutions at accessible price points for global markets, including high volume markets, where demand for new products continues to benefit from rapid growth in healthcare spending and population growth. 

Alongside this announcement, AXA IM Alts is pleased to share that it has appointed two new Partners to lead the Strategy - Curt LaBelle and Zina Affas Besse as Head and Deputy Head of Healthcare Private Equity, respectively, as a natural continuation of its existing private equity healthcare expertise. Each with over 20 years’ experience within healthcare and investing, Curt and Zina bring a wealth of experience and strong track record in investing, advising, and operating in healthcare start-ups globally, including running Global Health Investment Advisors. Curt and Zina join Alexandre Martin-Min, Managing Partner, CIO Structured Finance and Impact Private Equity and Jonathan Dean, Partner, Head of Fund Management Impact Private Equity at AXA IM Alts who are responsible for the impact investing platforms. This group forms the investment committee leading the newly launched Global Health Strategy.